menu
    • menu
    [{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":1.05,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.05,"dosageForm":"Cream","sponsorNew":"Torii Pharmaceutical \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Shionogi"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Nogra Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NAC-GED-0507","moa":"PPA-gamma receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film-Forming Solution","sponsorNew":"Torii Pharmaceutical \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film-Forming Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Torii Pharmaceutical","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Torii Pharmaceutical

    Menu

    Torii Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $29.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verrica Announces Amendment to Collaboration and License Agreement with Torii

                            Details : The agreement aims to initiate a global pivotal Phase 3 clinical trial of Verrica’s product, Ycanth (cantharidin), for the treatment of common warts.

                            Product Name : Ycanth

                            Product Type : Other Small Molecule

                            Upfront Cash : $11.5 million

                            July 01, 2025

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $29.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Shionogi

                            Deal Size : $1,050.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Shionogi to buy Japan Tobacco's Unit Torii Pharmaceutical for $1 billion

                            Details : The two companies would strengthen its domestic business by strengthening sales and marketing channels in dermatology including Vtama (tapinarof), paediatrics, and otolaryngology.

                            Product Name : Vtama

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 07, 2025

                            Lead Product(s) : Tapinarof

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Shionogi

                            Deal Size : $1,050.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Verrica Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Torii Files NDA in Japan for TO-208 in Molluscum Contagiosum

                            Details : TO-208 previously known as VP-102 is a single-use drug device combination product containing (cantharidin) topical solution. It is being evaluated for the treatment of Molluscum Contagiosum.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 06, 2024

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Verrica Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Verrica Amends Collaboration with Torii to Fund Phase 3 Trial for YCANTH®

                            Details : Through the licensing agreement with Torii Pharmaceutical, to jointly conduct a global pivotal Phase 3 clinical trial studies of Ycanth (cantharidin) for the treatment of common warts.

                            Product Name : Ycanth

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 15, 2024

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAC-GED-0507

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Nogra Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Torii Has Entered Into a License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 i...

                            Details : Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of ...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 26, 2023

                            Lead Product(s) : NAC-GED-0507

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Nogra Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum ...

                            Details : VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.

                            Product Name : Ycanth

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 08, 2022

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $15.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treat...

                            Details : Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

                            Product Name : Orladeyo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 14, 2021

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $15.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $69.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical for VP-102

                            Details : Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted adm...

                            Product Name : Ycanth

                            Product Type : Other Small Molecule

                            Upfront Cash : $11.5 million

                            March 17, 2021

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $69.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $70.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102...

                            Details : The agreement grants Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.

                            Product Name : Ycanth

                            Product Type : Other Small Molecule

                            Upfront Cash : $11.5 million

                            May 08, 2020

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $70.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $42.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioCryst Submits Japanese NDA for Oral, Once Daily Berotralstat

                            Details : Torii Pharmaceutical will pay tiered royalties of up to 40 percent of Japanese net sales of berotralstat to BioCryst upon receipt of a reimbursement price approval NHI Japan.

                            Product Name : Orladeyo

                            Product Type : Other Small Molecule

                            Upfront Cash : $22.0 million

                            March 02, 2020

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $42.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth